Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

Cancer Commun (Lond). 2023 Apr 26. doi: 10.1002/cac2.12425. Online ahead of print.

Leena Karimi¹, Carla L Alves¹, Mikkel G Terp¹, Martina Tuttolomondo¹, Neil Portman^{2

3}, Sidse Ehmsen^{1

4}, Lene E Johansen¹, Martin Bak⁵, Elgene Lim^{2

3}, Henrik J Ditzel^{1

4

6}

¹ Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
² Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
³ St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, New South Wales, Australia.
⁴ Department of Oncology, Institute of Clinical Research, Odense University Hospital, Odense, Denmark.
⁵ Department of Pathology, Sydvestjysk Sygehus, Esbjerg, Denmark.
⁶ Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.

No abstract available

Publication types